RxDoctor Payments Data

Elmer Tu, MD

Ophthalmology · Chicago, ILNPI 1730192436

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,153 of the $20,946 with a category attached, or 62.8%. 11 manufacturers reported payments, led by Dompe US, Inc. at 28.3% of the total. Reporting peaked in 2020 at $6,725 and has fallen 99.7% since, to $23 in 2024. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,946in general payments, 2019–2025

Across 24 payments — averaging $872.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$6K
  • Seagen Inc.$5K
  • Oyster Point Pharma, Inc.$2K
  • Astrazeneca UK Limited$2K
  • Daiichi Sankyo Inc.$2K
  • GSK$2K
  • plus $2K from 5 others

What the payments were for

  • Consulting fees$13,15363%
  • Speaking & faculty fees$7,20034%
  • Travel & lodging$510%
  • Food & beverage$5423%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,946 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois →

Medicare billing

Part B allowed, 2024
$174,818
Medicare patients
510
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate242$10,177
Difluprednate22$8,334
Loteprednol Etabonate28$3,651
Fluorometholone29$2,460
Timolol Maleate47$2,124
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,503
ValacyclovirValacyclovir Hcl19$1,030
Latanoprost84$774
Brimonidine Tartrate62$589
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$507
MoxifloxacinMoxifloxacin Hcl13$442
Ofloxacin16$198
ErythromycinErythromycin Base14$135
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim13$99

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Chicago

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →